Boston Scientific Corp. Hits New 52-Week Low at $71.83

Boston Scientific Corp. has reached a significant milestone by touching a new 52-week low of USD 71.83 on March 4, 2026. This decline reflects a 6.73% decrease in the company's stock price over the past year, contrasting sharply with the S&P 500's performance, which has seen a gain of 17.36% during the same period. As a large-cap player in the retailing industry, Boston Scientific Corp. boasts a market capitalization of USD 130,304 million. The company's price-to-earnings (P/E) ratio stands at 69.00, indicating a premium valuation compared to its earnings. Additionally, the firm has a debt-to-equity ratio of 0.39, suggesting a relatively low level of debt compared to its equity. The return on equity is reported at 13.88%, reflecting the company's ability to generate profits from its shareholders' investments. However, it is noteworthy that Boston Scientific does not currently offer a dividend yield. This recent price movement highlights the ongoing dynamics within the market and the company's position within the retailing sector.